论文部分内容阅读
目的评估依达拉奉和单唾液酸四己糖神经节苷脂(GM_1)联合治疗急性期脑梗死的协同作用。方法选择广东省东莞市塘厦人民医院2005年8月至2007年2月收治的71例急性期脑梗死患者随机分为常规治疗组(常规应用复方丹参注射液,肠溶阿司匹林治疗)18例,依达拉奉组(常规治疗加依达拉奉)17例,GM_1组(常规治疗加 GM_1)18例,联合治疗组(常规治疗加依达拉奉和 GM_1)18例。观察4组治疗前后按美国国立卫生研究院卒中量表(NIHSS)评分、Barthel 指数(BI)和治疗后不良反应的发生率。结果依达拉奉组、GM_1组和联合治疗组急性期脑梗死患者 NIHSS 评分均降低(依达拉奉:F=12.36,P<0.01;GM_1:F=6.94,P<0.01;F=37.52,P<0.01);BI 评分均升高(依达拉奉:F=15.46,P<0.01;GM_1:F=6.39,P<0.01;F=26.75,P<0.01)。结论依达拉奉和 GM_1联用可以减轻急性期脑梗死患者的神经功能缺损,增强日常生活能力,较各自单独应用疗效更好,具有协同作用。
Objective To evaluate the synergistic effect of edaravone and monosialotetrahexosyl ganglioside (GM_1) in the treatment of acute cerebral infarction. Methods Totally 71 acute cerebral infarction patients admitted from August 2005 to February 2007 in Tangxia People’s Hospital of Dongguan City of Guangdong Province were randomly divided into routine treatment group (routine use of compound Salvia miltiorrhiza injection, enteric-coated aspirin treatment) 18 cases, Edaravone group (conventional treatment plus edaravone) in 17 cases, GM_1 group (conventional treatment plus GM_1) in 18 cases, combined treatment group (conventional treatment plus edaravone and GM_1) in 18 cases. The incidences of NIHSS, Barthel Index (BI) and adverse reactions after treatment were observed before and after treatment in the 4 groups. Results The NIHSS scores of patients in edaravone group, GM_1 group and combination group were both decreased (Edaravone: F = 12.36, P <0.01; GM_1: F = 6.94, P <0.01; F = 37.52, P <0.01); BI scores were increased (edaravone: F = 15.46, P <0.01; GM_1: F = 6.39, P <0.01; F = 26.75, P <0.01). Conclusion The combination of edaravone and GM_1 can reduce the neurological deficits and enhance the daily living ability of patients with acute cerebral infarction, which is better than that of GM_1 alone and has a synergistic effect.